flutiform 250+10 mikrogram inhalationsspray, suspension
mundipharma a/s - fluticasonpropionat, formoterolfumarat dihydrat - inhalationsspray, suspension - 250+10 mikrogram
flutiform k-haler 125+5 mikrogram inhalationsspray, suspension
mundipharma a/s - fluticasonpropionat, formoterolfumarat dihydrat - inhalationsspray, suspension - 125+5 mikrogram
flutiform k-haler 50+5 mikrogram inhalationsspray, suspension
mundipharma a/s - fluticasonpropionat, formoterolfumarat dihydrat - inhalationsspray, suspension - 50+5 mikrogram
zoledronic acid accord
accord healthcare s.l.u. - zoledronsyremonohydrat - hypercalcemia; fractures, bone; cancer - bisfosfonater - forebyggelse af skeletrelaterede hændelser (patologiske frakturer, rygkompression, stråling eller operation til knogle eller tumorinduceret hypercalcæmi) hos voksne patienter med avancerede maligniteter, der involverer knogle. behandling af voksne patienter med tumor-induceret hypercalcaemia (tih).
tranexamic acid "baxter" 100 mg/ml injektions-/infusionsvæske, opløsning
baxter holding b.v. - tranexamsyre - injektions-/infusionsvæske, opløsning - 100 mg/ml
wakil multi pepite pulver
syngenta nordics a/s - carbendazim, thiram, cymoxanil, oxadixyl - pulver - 167 g/kg carbendazim ; 334 g/kg thiram ; 67 g/kg cymoxanil ; 167 g/kg oxadixyl
wakil xl 32,5 wg vanddispergerbart granulat
syngenta nordics a/s - fludioxonil, cymoxanil, metalaxyl-m - vanddispergerbart granulat - 50 g/kg fludioxonil ; 100 g/kg cymoxanil ; 175 g/kg metalaxyl-m
d-acid flydende middel
klarsø a/s - 2,4-d - flydende middel - 500 g/l 2,4-d
samsca
otsuka pharmaceutical netherlands b.v. - tolvaptan - uheldig adh-syndrom - diuretika, - behandling af voksne patienter med hyponatriæmi, der er sekundær for syndrom med upassende antidiuretisk-hormonsekretion (siadh).
zomarist
novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.